论文部分内容阅读
目的:分析血清miR-21(SmiR-21)联合尿微量白蛋白(UmA1b)、尿微量白蛋白(UmA1b)与尿肌酐比值(Ucr)在糖尿病肾病诊断中的应用,评价其临床价值。方法:设43例糖尿病肾病患者为研究对象(研究组),与同期于我院接受健康体检40例血清(参照组)展开对比,总结两组对象各检测指标表现。结果:研究组SmiR-21联合UmA1b与UmA1b/Ucr水平明显高于参照组(P<0.05)。结论:SmiR-21联合UmA1b、UmA1b/Ucr应用于诊断糖尿病肾病诊断中效果确切,通过多项指标结合检查更具优势,可作为糖尿病肾病患者临床诊断首选指标组合。
Objective: To evaluate the clinical value of serum miR-21 (SmiR-21) in combination with urinary microalbuminuria (UmA1b), urinary microalbuminuria (UmA1b) and urinary creatinine ratio (Ucr) in the diagnosis of diabetic nephropathy. Methods: Forty-three patients with diabetic nephropathy (study group) were enrolled in this study. Contrasting with 40 cases of healthy subjects in our hospital during the same period (reference group), the performance of each test group was summarized. Results: The levels of SmiR-21, UmA1b and UmA1b / Ucr in the study group were significantly higher than those in the reference group (P <0.05). Conclusion: The combination of SmiR-21 with UmA1b and UmA1b / Ucr can be used in the diagnosis of diabetic nephropathy. The combination of SmiR-21 and UmA1b / Ucr can be used as the first choice of clinical diagnosis in patients with diabetic nephropathy.